A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

A HER3 antibody that uniquely blocks the HER3 heterodimerization
interface effectively inhibits tumor growth in pre-clinical
models with potentially oncogenic HER3 mutations

Leave a Reply